This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!
KDIGO CKD GUIDELINES - VISUAL ABSTRACT
Check out the TOP 10 takeaways from KDIGO - CKD guidelines on evaluation of people with or at risk of CKD by NSMC Intern Stephanie Torres
🤔 Does BP lowering matter for the kidneys after all?
Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes (Ku, JASN 2023)
🤔 Coffee and the kidneys
CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction (Mahdavi, JAMA Network Open 2023)
🤔 Improving decision making in CKD
Effectiveness of an Intervention to Improve Decision Making for Older Patients With Advanced Chronic Kidney Disease (Ladin, Annals Int Med 2023)
🤔 Screening for albuminuria is cost-effective
Population-Wide Screening for Chronic Kidney Disease: A Cost-Effectiveness Analysis (Cusick, Annals Int Med 2023)
🤔 RASi + diuretics better than RASi + CCB in CKD?
A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality (Faucon, Kidney International 2023)
🤔 A digital intervention to increase physical activity in CKD
Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UK (The EMPA-KIDNEY Collaborative Group The Lancet Digital Health 2024)
🤔 EMPA KIDNEY analysis by CKD diagnosis
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)
🤔 EMPA Kidney sub-group analysis by DM and ACR status
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)
🤔 Albuminuria reduction drives Finerenone's kidney benefit
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes (Agarwal et al, Annals IM 2023)